Number Of The Day | 14% | 23 April 2026
14%. That is the share of surveyed higher-income South Africans who report spending on prescribed weight-management medication.
Gareth Edwards and Francis Herd start with that stat, then follow the tension inside it. On one side is the appeal: visible results, rising demand, and a growing consumer willingness to spend on GLP-1 therapies. On the other is the unease: who these medicines were originally designed for, what happens when treatment stops, and whether the long-term picture is being taken seriously enough. The transcript keeps returning to that friction between promise and caution.
The wider market helps explain why the number lands so hard. SpendTrend26 says 14% of surveyed credit card holders earning above R100,000 a year report spending on prescribed weight-loss medication, while 16% report spending on dieticians or weight-loss clinics. Among households using the medicines, budgets are also being materially reshaped across healthier foods, takeaways, and alcohol.
South Africa’s private-sector GLP-1 market has been moving fast. Wegovy launched locally in 2025 for weight management, Mounjaro has also expanded into that space, and the category remains costly enough to skew heavily toward people with money or coverage.
14% is the entry point. The bigger story is what South Africans are prepared to pay for, what they are hoping these drugs can solve, and how fast demand is rising before the country has fully settled the questions around access, sustainability, and safety.
Catch up on all Number of the Day episodes here: https://www.enca.com/number-day-podcast
